Search Results

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology indications, announced the appointment of John Healy as General Counsel & Corporate Secretary.

Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the first quarter of 2024 and provided general business updates.

Elanco Animal Health (NYSE: ELAN) announced today the appointment of Shiv O’Neill as the company’s Executive Vice President, General Counsel and Corporate Secretary.

Driven by copycat versions of Bristol Myers Squibb’s Revlimid and Novo Nordisk’s Victoza, Teva’s generics business was again a top-performer in the third quarter, with U.S. sales growing 30% and bringing in $1.1 billion in sales.

Amarin Corporation plc announced shareholder approval of all proposed resolutions specified at its 2024 Annual General Meeting.

Theralase® Technologies Inc. is providing a reminder notice for its Annual General and Special Meeting for shareholders of Theralase® that is scheduled for Wednesday, June 19th at 4:30 pm ET at its corporate head office; specifically, 41 Hollinger Road, Toronto, Ontario, M4B 3G4.